<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="Manag.201710397405 49.GreerG.R.GrobC.S.HalberstadtA.L.PTSD Symptom Reports of Patients Evaluated for the New" exact="Mexico" post="Medical Cannabis ProgramJ. Psychoact. Drugs201446737710.1080/02791072.2013.873843 50.Bonn-MillerM.O.BodenM.T.BucossiM.M.BabsonK.A.Self-reported cannabis use characteristics,"/>
 <result pre="= 8.181, p = 0.006). Smith et al. [48] 2017," exact="Canada" post="2 years, variable treatment duration and time to follow-up"/>
 <result pre="p &amp;lt; 0.0001) after treatment. Cameron et al. [40] 2014," exact="Canada" post="43 months Retrospective studyGrade: ** N = 104 males;"/>
 <result pre="= 39.87, p &amp;lt; 0.0001). Jetly et al. [39] 2014," exact="Canada" post="Two periods of 7 weeks separated by a period"/>
 <result pre="score after treatment with nabilone. Roitman et al. [37] 2014," exact="Israel" post="3 weeks Non-randomized, open-label, adjusted doses, studyGrade: *** N"/>
 <result pre="for social anxiety problems (p &amp;lt; 0.004). Reznik [51] 2012," exact="Israel" post="3 years Naturalistic observational studyGrade: ** N = 16725"/>
 <result pre="of improved subjects belonged to comorbidity groups. Fraser [38] 2009," exact="Canada" post="2 years of clinical observation; flexible duration of treatment"/>
</results>
